Probiotics ( DrugBank: - )

---

5 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	5
94	Primary sclerosing cholangitis	1
96	Crohn disease	4
97	Ulcerative colitis	11
291	Hirschsprung disease, entire colon type	3

6. Parkinson disease

---

Clinical trials : 2,307 /  Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05173701 (ClinicalTrials.gov)	November 22, 2021	8/11/2021	Effects of Probiotics on Peripheral Immunity in Parkinson's Disease	Effects of Probiotics on Peripheral Immunity in Parkinson's Disease	Parkinson's Disease	Dietary Supplement: Probiotics;Dietary Supplement: Placebo	Franca Marino	Università degli Studi del Piemonte Orientale Amedeo Avogadro;Università degli Studi dell'Insubria	Enrolling by invitation	N/A	N/A	All	88	N/A	Italy
2	NCT04871464 (ClinicalTrials.gov)	November 11, 2021	29/4/2021	Role and Mechanism of Probiotics in Improving Motor Symptoms in Mild to Moderate Parkinson's Disease	Role and Mechanism of Bifidobacterium Triple Viable Capsules in Improving Motor Symptoms in Patients With Mild to Moderate Parkinson's Disease: a Multicenter Randomized Clinical Study	Parkinson Disease;Parkinsonian Disorders;Basal Ganglia Diseases;Brain Diseases;Movement Disorders;Neurodegenerative Diseases;Central Nervous System Diseases;Nervous System Diseases	Drug: Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules;Other: Placebo	Beijing Friendship Hospital	NULL	Recruiting	40 Years	85 Years	All	240	Phase 4	China
3	NCT05146921 (ClinicalTrials.gov)	July 4, 2019	2/11/2021	Gut Health and Probiotics in Parkinson's (SymPD)	Gut Health and Probiotics in Parkinson's (SymPD)	Parkinson Disease	Dietary Supplement: Multi-strain probiotic;Other: Placebo	King's College Hospital NHS Trust	King's College London	Active, not recruiting	18 Years	N/A	All	60	N/A	United Kingdom
4	NCT04451096 (ClinicalTrials.gov)	October 6, 2018	19/6/2020	Probiotics-prebiotic Fiber Therapy in Parkinson's Disease Patients With Constipation	Probiotics-prebiotic Fiber Therapy Improved Bowel Opening Frequency and Whole Gut Transit Time in Parkinson's Disease Patients With Constipation: A Randomised Controlled Study	Parkinson Disease;Constipation	Dietary Supplement: Probiotics with prebiotic;Dietary Supplement: Placebo	National University of Malaysia	NULL	Completed	18 Years	N/A	All	48	Phase 3	Malaysia
5	NCT03377322 (ClinicalTrials.gov)	December 1, 2017	7/12/2017	Trial of Probiotics for Constipation in Parkinson's Disease	A Randomized Double-Blinded Placebo-Controlled Trial of Probiotics for Constipation in Parkinson's Disease	Parkinson Disease	Drug: Probiotic Capsule;Drug: Placebo Capsule	University of Malaya	NULL	Completed	40 Years	85 Years	All	72	N/A	Malaysia

Back to top

94. Primary sclerosing cholangitis

---

Clinical trials : 148 /  Drugs : 118 - (DrugBank : 39) / Drug target genes : 18 - Drug target pathways : 141

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00161148 (ClinicalTrials.gov)	January 2005	8/9/2005	Probiotics in Patients With Primary Sclerosing Cholangitis	Probiotics in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Disease- a Randomized Placebo-Controlled Cross-Over Trial	Primary Sclerosing Cholangitis	Drug: Probiotics	UMC Utrecht	NULL	Recruiting	18 Years	N/A	Both	12	Phase 3	Netherlands

96. Crohn disease

---

Clinical trials : 2,442 /  Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01765998 (ClinicalTrials.gov)	February 2013	6/1/2013	The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease)	The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) and Markers of Inflammation	Crohn's Disease	Drug: Probiotic;Drug: Placebo	The Baruch Padeh Medical Center, Poriya	NULL	Not yet recruiting	18 Years	60 Years	Both	60	Phase 4	Israel
2	NCT01078935 (ClinicalTrials.gov)	December 2012	1/3/2010	The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation, Endothelial Function, and Markers of Inflammation	The Effect of Probiotics on Bowel Disease	Crohn's Disease;Ulcerative Colitis	Dietary Supplement: probiotics;Dietary Supplement: placebo	The Baruch Padeh Medical Center, Poriya	Ministry of Health, Israel	Not yet recruiting	18 Years	80 Years	Both	100	Phase 4	NULL
3	NCT00587041 (ClinicalTrials.gov)	February 2006	21/12/2007	Use of Oral Probiotics to Reduce Urinary Oxalate Excretion	Use of Oral Probiotics to Reduce Urinary Oxalate Excretion	Nephrolithiasis;Hyperoxaluria;Crohn's Disease	Dietary Supplement: Oxadrop;Dietary Supplement: Agri-King Synbiotic (AKSB);Other: Placebo	Mayo Clinic	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);National Institutes of Health (NIH);National Center for Complementary and Integrative Health (NCCIH);National Center for Research Resources (NCRR)	Completed	18 Years	N/A	All	40	Phase 1/Phase 2	United States
4	NCT00510978 (ClinicalTrials.gov)	January 2002	2/8/2007	Probiotics in GastroIntestinal Disorders	One Year, Randomised, Double Blind, Placebo Controlled Trial of Probiotics, Bifidobacterium Infantis 35624 or Lactobacillus Salivarius UCC118, as Food Supplements for Maintenance of Remission in Crohn's Disease and Ulcerative Colitis	Ulcerative Colitis;Crohn's Disease	Biological: Bifidobacterium infantis 35624;Biological: Lactobacillus salivarius UCC118;Biological: Placebo	University College Cork	European Commission	Active, not recruiting	N/A	75 Years	Both	360	Phase 2/Phase 3	Ireland

97. Ulcerative colitis

---

Clinical trials : 2,630 /  Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05579483 (ClinicalTrials.gov)	December 2022	4/10/2022	Prediction of Dietary Intervention Efficacy in Mild Ulcerative Colitis Patients Based on Fecal Microbiome Signatures	Prediction of Dietary Intervention Efficacy in Mild Ulcerative Colitis Patients Based on Fecal Microbiome Signatures	Ulcerative Colitis	Dietary Supplement: Prebiotics;Dietary Supplement: Placebo	Wageningen University	Winclove Probiotics B.V.;China Scholarship Council	Not yet recruiting	18 Years	65 Years	All	60	N/A	Netherlands
2	NCT05652621 (ClinicalTrials.gov)	July 31, 2022	9/9/2022	Efficacy of Probiotics in Patients With IBD	Clinical Efficacy and Mechanism of Probiotics in the Adjuvant Treatment of Ulcerative Colitis and Irritable Bowel Syndrome	Ulcerative Colitis;Irritable Bowel Syndrome	Dietary Supplement: probiotics	The First Affiliated Hospital of Xinxiang Medical College	NULL	Recruiting	18 Years	80 Years	All	200	N/A	China
3	ChiCTR2100046446	2021-07-01	2021-05-15	Effect of probiotics supplementation combined with WeChat platform health management on nutritional status, inflammatory factors, and quality of life in patients with mild-to-moderate ulcerative colitis	Effect of probiotics supplementation combined with WeChat platform health management on nutritional status, inflammatory factors, and quality of life in patients with mild-to-moderate ulcerative colitis	ulcerative colitis	experimental group:Bifidobacterium triple live bacteria combined with WeChat platform for health management intervention;control group:Mesalazine Oral;	Affiliated Hospital of Jiangnan University	NULL	Recruiting	18	80	Both	experimental group:70;control group:70;	N/A	China
4	ChiCTR2000032498	2020-09-01	2020-04-30	Human experimental study on the effect of probiotics combined with prebiotics on ulcerative colitis: a randomized double-blind controlled trial	Human experimental study on the effect of probiotics combined with prebiotics on ulcerative colitis	Ulcerative colitis	Experimental group:Probiotics and prebiotics;placebo group:maltodextrin;	Capital Medical University	NULL	Pending			Both	Experimental group:15;placebo group:15;		China
5	NCT04006977 (ClinicalTrials.gov)	October 2019	1/7/2019	Multistrain Probiotics Reduces UC Depression and Anxiety Scores	Multistrain Probiotic Product (De Simone Formulation) Reduces Depression and Anxiety Scores: a Randomized Pilot Study in Patients With Ulcerative Colitis	Ulcerative Colitis	Dietary Supplement: a multistrain probiotic product (DSF);Dietary Supplement: Placebo	Xijing Hospital of Digestive Diseases	MENDES SA	Not yet recruiting	18 Years	65 Years	All	60	N/A	China
6	ChiCTR1900022243	2019-04-01	2019-03-31	Effect of curcumin combined with probiotics on prevention and treatment in ileal pouchitis after operation of ulcerative colitis.	Effect of curcumin combined with probiotics on prevention and treatment in ileal pouchitis after operation of ulcerative colitis.	ileal pouchitis after operation of ulcerative colitis	Experimental group:Curcumin+Probiotics;Control group:Probiotics;	Tianjin Medical University General Hospital	NULL	Recruiting			Both	Experimental group:20;Control group:10;		China
7	NCT04969679 (ClinicalTrials.gov)	March 16, 2018	7/7/2021	Additive Effect of Probiotics (Mutaflor®) in Patients With Ulcerative Colitis on 5-ASA Treatment.	A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effect of Mutaflor in Patients With Mild-to-moderate Ulcerative Colitis on 5-ASA Treatment.	Ulcerative Colitis	Drug: E. coli Nissle 1917 (Mutaflor®);Drug: Placebo	Kangbuk Samsung Hospital	NULL	Completed	19 Years	N/A	All	134	Phase 4	Korea, Republic of
8	ChiCTR-IPR-17010306	2017-02-01	2017-01-01	Effects of probiotics on intestinal microecological reconstruction in patients with ulcerative colitis	Effects of probiotics on intestinal microecological reconstruction in patients with ulcerative colitis	Ulcerative colitis	Group A:Mesalazine combined with placebo; Group B:Methalazine combined with probiotics;Group C:Probiotics combined with placebo;Normal control group:Blank control;	Affiliated Hospital of Inner Mongolia Medical University	NULL	Pending	18		Both	Group A:30; Group B:30;Group C:30;Normal control group:30;		China
9	NCT01078935 (ClinicalTrials.gov)	December 2012	1/3/2010	The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation, Endothelial Function, and Markers of Inflammation	The Effect of Probiotics on Bowel Disease	Crohn's Disease;Ulcerative Colitis	Dietary Supplement: probiotics;Dietary Supplement: placebo	The Baruch Padeh Medical Center, Poriya	Ministry of Health, Israel	Not yet recruiting	18 Years	80 Years	Both	100	Phase 4	NULL
10	NCT00578799 (ClinicalTrials.gov)	December 2007	18/12/2007	Effects of Probiotics in Patients With Ulcerative Colitis	Effects of Probiotics in Patients With Ulcerative Colitis.	Ulcerative Colitis	Dietary Supplement: Kyo-Dophilus;Dietary Supplement: placebo	University of California, Irvine	Wakunaga Pharmaceutical Co., Ltd.	Withdrawn	18 Years	65 Years	All	0	Phase 1	United States
11	NCT00510978 (ClinicalTrials.gov)	January 2002	2/8/2007	Probiotics in GastroIntestinal Disorders	One Year, Randomised, Double Blind, Placebo Controlled Trial of Probiotics, Bifidobacterium Infantis 35624 or Lactobacillus Salivarius UCC118, as Food Supplements for Maintenance of Remission in Crohn's Disease and Ulcerative Colitis	Ulcerative Colitis;Crohn's Disease	Biological: Bifidobacterium infantis 35624;Biological: Lactobacillus salivarius UCC118;Biological: Placebo	University College Cork	European Commission	Active, not recruiting	N/A	75 Years	Both	360	Phase 2/Phase 3	Ireland

Back to top

291. Hirschsprung disease, entire colon type

---

Clinical trials : 12 /  Drugs : 24 - (DrugBank : 15) / Drug target gene : 0 - Drug target pathway : 0

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02343562 (ClinicalTrials.gov)	October 2014	9/1/2015	Probiotics for Prophylaxis of Postoperative Hirschsprungs Associated Enterocolitis	Probiotics for Prophylaxis of Postoperative Hirschsprungs Associated Enterocolitis	Hirschsprung Disease	Dietary Supplement: Probiotics;Dietary Supplement: Placebo	Cairo University	NULL	Unknown status	6 Months	12 Years	All	40	Phase 4	Egypt
2	NCT02350088 (ClinicalTrials.gov)	January 2014	17/1/2015	Fast-track Surgery in the Treatment of Hirschsprung's Disease	Fast-track Surgery in the Treatment of Hirschsprung's Disease	Surgery	Drug: probiotics;Drug: placebo	Tongji Hospital	Children's Hospital Boston	Recruiting	1 Year	18 Years	Both	100	N/A	China
3	NCT01934959 (ClinicalTrials.gov)	January 2008	21/8/2013	A Trial on Probiotics in Preventing Hirschsprung's Disease Associated Entercolitis	A Prospective Multicenter Randomized Controlled Trial on Probiotics in Preventing Hirschsprung's Disease Associated Entercolitis	Probiotics;Hirschsprung's Disease Associated Enterocolitis	Drug: Bifico	Tongji Hospital	Anhui Provincial Hospital	Completed	1 Month	13 Years	Both	60	Phase 0	NULL

Back to top